Clinical

CytomX Lands $80M to Kick Off Cancer Drug R&D Pact With Astellas

14 days ago   |   By Xconomy

CytomX Therapeutics is teaming up with Astellas Pharma in a research and development alliance focused on developing new cancer immunotherapies based on its antibody technology. Under deal terms announced late Monday, Astellas is paying CytomX $80 million up front. South San Francisco-based CytomX will conduct and finance the research up to the selection of drug candidates. Astellas will take the lead from there, funding preclinical and clinical research. Depending on the progress of those programs, Tokyo-based Astellas could pay CytomX up to $1.6 billion more, plus royalties from sales of...
Read more ...

 

CytomX pens $1.6B Astellas biobucks pact for T-cell R&D

CytomX pens $1.6B Astellas biobucks pact for T-cell R&D

14 days ago   |   By Fierce Biotech

With $80 million upfront and up to $1.6 billion in biobucks, Astellas is still ramping up the biotech deals after ending 2019 on a buyout high.
Read more ...

 


Search by Tags

   Clinical      Drug      R&D      Cancer      Drugs      Therapeutics      Pharma      Research      National blog main      National top stories      San Francisco      San Francisco blog main      San Francisco top stories      Seattle blog main      Seattle top stories      AbbVie      Astellas Pharma      Audentes Therapeutics      Biotech      Breast Cancer      Bristol-myers Squibb      Cancer      Cancer immunotherapy      Clinical trials      CytomX Therapeutics      Deals      Life Sciences      Melanoma      Multiple Myeloma      Universal Cells      BioTech  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Convalescent Plasma: A Therapy for COVID-19?

Convalescent Plasma: A Therapy for COVID-19?

To develop a treatment for patients with COVID-19, researchers around the world are steadfastly exploring numerous angles, including testing existing antiviral drugs and new... Read more ...

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA's OK to start testing its candidate in healthy volunteers. The... Read more ...

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

Sage Therapeutics is cutting workers who sell its only commercialized drug in a corporate reorganization that it says allows it to focus on clinical-stage compounds, including... Read more ...

Creating Consistent Value in Biotech Without Diluting Stakeholders

Creating Consistent Value in Biotech Without Diluting Stakeholders

One of the greatest challenges for pre-commercial biotech companies is consistently generating capital necessary for operating costs and for R&D of new products that provide... Read more ...

Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13

Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13

In the Boston biotech hub, much progress has been made advancing digital health, but significant scientific, technological, financial, and regulatory challenges remain. Join us... Read more ...

Millendo May Restructure After Prader-Willi Drug Fails Pivotal Test

Millendo May Restructure After Prader-Willi Drug Fails Pivotal Test

Millendo Therapeutics is considering a corporate reorganization after its lead drug, an investigational treatment for a rare genetic condition characterized by unrelenting... Read more ...

Menlo's Itching Drug Racks Up Two More Trial Failures, Program Ends

Menlo's Itching Drug Racks Up Two More Trial Failures, Program Ends

An itching drug that was a key part of the merger of Menlo Therapeutics and Foamix Pharmaceuticals has failed two late-stage studies, leading to a halt on further development... Read more ...

Premier Biomedical Realigns Business to Eliminate Convertible Debt, Cancel...

Premier Biomedical Realigns Business to Eliminate Convertible Debt, Cancel Reverse Split & Fund Covid-19 R&D

Jackson Center, PA, April 6, 2020 - Premier Biomedical, Inc. announced a multi-faceted agreement to eliminate the Convertible Notes as an obligation of Premier, cancel the... Read more ...

GSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months

GSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months

GlaxoSmithKline has agreed to invest $250 million in infectious disease specialist Vir Biotechnology to launch a COVID-19 R&D alliance that the companies say could advance two... Read more ...

Xconomy Releases Coronavirus Special Report on Containing the Pandemic...

Xconomy Releases Coronavirus Special Report on Containing the Pandemic Through Innovation & Investment

Based on the latest news and analysis, as well as conversations from industry experts during the Combatting Coronavirus live panel at BIO-Europe Spring®, Xconomy's free special... Read more ...